Search Results

Fullpower Technologies, in collaboration with Stanford Sleep Medicine and UCSF Department of Psychiatry and Behavioral Sciences, presented two major studies at the SLEEP 2024 conference, furthering our understanding of sleep fragmentation and heart rate variability (HRV) during sleep.

Eureka Therapeutics, Inc. today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).

In a study published online in CELL , scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers.

AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the commencement of an investigator initiated Phase 2 study at UC San Francisco (UCSF) for its novel inhaled form of sirolimus, LAM-001, for the treatment of bronchiolitis obliterans syndrome (BOS) in patients post-lung transplant.

UC San Francisco (UCSF) is conducting a six-month clinical trial on hypertrophic cardiomyopathy (HCM) using Vivalink’s Biometrics Data Platform.

ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the site initiation visits (SIV) at the University of California San Francisco (UCSF) Medical Center was conducted on March 29, 2023.

Delve Bio in collaboration with the University of California, San Francisco (UCSF), today announced data from a study highlighting the utility and diagnostic yield of mNGS testing in cases of infectious meningitis, encephalitis, and/or myelitis among both adults and children at the American Society of Microbiology Microbe conference in Atlanta.

Harmonic Discovery announced an exclusive licensing agreement of a novel small-molecule drug candidate for the treatment of FLT3 mutated acute myeloid leukemia from BioVentures and UC San Francisco.

Delve Bio in collaboration with the University of California, San Francisco (UCSF), today announced data on the use of mNGS for the diagnosis of infectious causes of meningitis and/or encephalitis in real-world clinical settings.

Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal cancer.